Colorectal neuroendocrine tumors (NETs) originate from neuroendocrine cells in the intestinal tract, and represent a small area within oncology, but one which has provided increasing new data during the past years. Although the World Health Organization has determined clinical and histological features to predict prognosis for such tumors, they may not be valid on an individual basis. We aim to give an overview of the recent findings with regard to pathology, molecular genetics and diagnosis of NETs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852818 | PMC |
| http://dx.doi.org/10.3748/wjg.v16.i14.1713 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival outcomes of poorly differentiated colorectal carcinoma variants: Insights from a single teaching institute.
Hum Pathol
December 2024
Henry Ford Health, Detroit, MI, USA; Michigan State University College of Human Medicine, East Lansing, MI, USA. Electronic address:
The morphologic diagnosis of colorectal carcinoma (CRC) is typically straight forward. However, there are certain subtypes of CRC that pose diagnostic challenges for daily practice due to sometimes overlapping morphologic and immunohistochemical features. These subtypes include poorly differentiated adenocarcinoma NOS, in the absence of conventional morphology (PDA-NOS), large cell neuroendocrine carcinoma (LCNEC), medullary carcinoma (MC), undifferentiated carcinoma (UC) and lymphoepithelioma-like carcinoma (LELC).
View Article and Find Full Text PDFThe clinical applications of dual-layer spectral detector CT in digestive system diseases.
Eur Radiol
December 2024
Depatment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Objective: Dual-layer spectral detector CT (DLCT) has several advantages in clinical practice, this study aims to reveal the clinical applications of DLCT in digestive system diseases.
Materials And Methods: We searched PubMed and Cochrane Reviews for articles published from January 1, 2010 to May 31, 2024, using the terms "dual-layer spectral detector CT" or "dual-layer CT" combined with "hepatic fat" or "hepatic fibrosis" "hepatocellular carcinoma" or "pancreatic ductal adenocarcinoma" or "pancreatic neuroendocrine tumors" or "gastric cancer" or "colorectal cancer" or "Crohn's disease" or "bowel ischemia" or "acute abdominal conditions".
Results: DLCT consists of a top layer sensitive to lower-energy photons and a bottom layer sensitive to higher-energy photons.
Investigating the Pathogenicity of Uncommon KRAS Mutations and Their Association with Clinicopathologic Characteristics in Patients with Colorectal Cancer.
J Mol Diagn
December 2024
Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Kirsten rat sarcoma viral oncogene homolog (KRAS) somatic mutations occur in 30% to 40% of patients with colorectal cancer (CRC). These were thought to equally affect prognosis and resistance to anti-epidermal growth factor receptor agents; however, recent data show the activity of KRAS-G12C and pan-RAS inhibitors. The effects of uncommon KRAS (uKRAS) variants are largely unexplored.
View Article and Find Full Text PDFPrognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
Eur J Cancer
January 2025
Digestive Surgery, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, Milan 20141, Italy. Electronic address:
Article Synopsis
- There has been a concerning rise in early-onset colorectal cancer (EO-CRC) cases, prompting research into how prognosis compares to late-onset colorectal cancer (LO-CRC).
- A systematic review of 26 studies found that EO-CRC patients are more likely to be diagnosed at advanced stages, yet they have better overall survival rates compared to LO-CRC patients, while other survival metrics like cancer-specific survival remain similar.
- The study highlights the need for better early detection methods for EO-CRC due to the differences in stage at diagnosis between the two groups.
Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas.
World J Gastrointest Oncol
December 2024
The 2 Department of Propaedeutic Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece.
Mixed neuroendocrine non-neuroendocrine neoplasms constitute rare tumors that are located mainly in the gastrointestinal (GI) tract and have high degrees of malignancy, and the frequency of these tumors has been increasing. They consist of a neuroendocrine neoplastic component with another component of adenocarcinoma usually and have a dismal prognosis. The rare GI pure neuroendocrine carcinoma is highly aggressive and requires complex and extensive management since a genetic distinction exists between it and GI non-neuroendocrine neoplasms, which are generally slow-growing lesions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!